These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 3459811)

  • 1. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis.
    Iacoboni SJ; Plunkett W; Kantarjian HM; Estey E; Keating MJ; McCredie KB; Freireich EJ
    J Clin Oncol; 1986 Jul; 4(7):1079-88. PubMed ID: 3459811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarubicin in blastic crisis of chronic myelogenous leukemia.
    Lambertenghi-Deliliers G; Annaloro C; Cortellaro M; Pozzoli E; Oriani A; Polli EE
    Haematologica; 1991; 76(5):406-8. PubMed ID: 1806446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
    Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
    Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses].
    Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
    Bauduer F; Delmer A; Blanc MC; Delmas-Marsalet B; Cadiou M; Rio B; Marie JP; Zittoun R
    Leuk Lymphoma; 1993 Jun; 10(3):195-200. PubMed ID: 8220118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
    Barone S; Baer MR; Sait SN; Lawrence D; Block AW; Wetzler M
    Am J Hematol; 2001 Jun; 67(2):119-24. PubMed ID: 11343384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
    Kantarjian HM; Estey EH; Plunkett W; Keating MJ; Walters RS; Iacoboni S; McCredie KB; Freireich EJ
    Am J Med; 1986 Sep; 81(3):387-94. PubMed ID: 3463209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea.
    Lazzarino M; Morra E; Brusamolino E; Alessandrino EP; Orlandi E; Pagnucco G; Castagnola C; Bernasconi P; Merante S; Bonfichi M
    Hematol Oncol; 1991; 9(6):299-305. PubMed ID: 1748396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged high dose ARA-C infusions in acute leukemia.
    Spriggs DR; Robbins G; Arthur K; Mayer RJ; Kufe D
    Leukemia; 1988 May; 2(5):304-6. PubMed ID: 3287017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
    Grant S; Baker M; Bhalla K
    Leukemia; 1993 Dec; 7(12):1933-8. PubMed ID: 8255091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia.
    Stone RM; Spriggs DR; Dhawan RK; Arthur KA; Mayer RJ; Kufe DW
    Leukemia; 1990 Dec; 4(12):843-7. PubMed ID: 2243507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.
    Marsh JH; Kreis W; Barile B; Akerman S; Schulman P; Allen SL; DeMarco LC; Schuster MW; Budman DR
    Cancer Chemother Pharmacol; 1993; 31(6):481-4. PubMed ID: 8453688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
    Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
    J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside.
    Kantarjian HM; Walters RS; Keating MJ; Talpaz M; Andersson B; Beran M; McCredie KB; Freireich EJ
    Cancer; 1988 Aug; 62(4):672-6. PubMed ID: 3165046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients.
    Powell BL; Capizzi RL; Muss HB; Bearden JD; Lyerly ES; Rosenbaum DL; Morgan TM; Richards F; Jackson DV; White DR
    Leukemia; 1989 Jan; 3(1):23-8. PubMed ID: 2642574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytosine arabinoside in the management of recurrent leukaemia.
    Ganesan TS; Barnett MJ; Amos RJ; Piall EM; Aherne GW; Man A; Lister TA
    Hematol Oncol; 1987; 5(1):65-9. PubMed ID: 3471699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.